Effect of Systemic Hydrocortisone Initiated 7 to 14 Days after Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial

Autor: Nienke M, Halbmeijer, Wes, Onland, Filip, Cools, Renate, Swarte, Marja, van der Heide-Jalving, Maruschka P, Merkus, Anton H, van Kaam, Elke, Dierckx

Publikováno v: JAMA-Journal of the American Medical Association, 326(4), 355-357. American Medical Association

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96444a670da78b914fa424feea6a5ddd
https://pure.amc.nl/en/publications/effect-of-systemic-hydrocortisone-initiated-7-to-14-days-after-birth-in-ventilated-preterm-infants-on-mortality-and-neurodevelopment-at-2-years-corrected-age-followup-of-a-randomized-clinical-trial(58ed3ca4-efea-4f1e-af53-4bb3adbea4ef).html

Prophylactic postnatal corticosteroids: Early hydrocortisone

Autor: Baud, Olivier, Watterberg, Kristi L

Publikováno v: Seminars in Fetal & Neonatal Medicine, Vol. 24, No 3 (2019) pp. 202-206

Inflammation is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in preterm infants, and cortisol plays a central role in controlling inflammation. Insufficient cortisol limits the ability of the sick newborn to handle stress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::123ae70fea71fd7aee60581979057bf4
https://archive-ouverte.unige.ch/unige:137442

Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial

Autor: Olivier, Baud, Laure, Maury, Florence, Lebail, Duksha, Ramful, Fatima, El Moussawi, Claire, Nicaise, Véronique, Zupan-Simunek, Anne, Coursol, Alain, Beuchée, Pascal, Bolot, Pierre, Andrini, Damir, Mohamed, Corinne, Alberti, Annick, Tibi

Publikováno v: The Lancet, Vol. 387, No 10030 (2016) pp. 1827-1836
Lancet
Lancet, Elsevier, 2016, 〈10.1016/S0140-6736(16)00202-6〉
The Lancet
The Lancet, 2016, ⟨10.1016/S0140-6736(16)00202-6⟩
Lancet, Elsevier, 2016, ⟨10.1016/S0140-6736(16)00202-6⟩

International audience; SummaryBackground Bronchopulmonary dysplasia, a major complication of extreme prematurity, has few treatment options. Postnatal steroid use is controversial, but low-dose hydrocortisone might prevent the harmful effects of inf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679db4209687895f848bdc74c231cd17
https://pubmed.ncbi.nlm.nih.gov/28961337

Caffeine therapy for apnea of prematurity

Autor: Schmidt, Barbara, Roberts, Robin S, Davis, Peter, Doyle, Lex W, Barrington, Keith J, Ohlsson, Arne, Solimano, Alfonso, Tin, Win, Pfister, Riccardo

Publikováno v: New England Journal of Medicine, Vol. 354, No 20 (2006) pp. 2112-21

Background Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b9686ec357d630a5512d180aeb44bc9
https://archive-ouverte.unige.ch/unige:46930

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.